Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What’s In A PDUFA Reauthorization? Maybe These Issues…

Jul 11 2011

Related Content

BIO’s "Big Ideas" For FDA Reform Are Too Big For PDUFA

Jul 04 2011

PDUFA V Agreement Appears Set Between FDA And Industry

Apr 28 2011

FDA Steps Into <i>Makena</i> Pricing Dispute In The Name Of "Access"

Apr 04 2011

CDER Reorganization Creates Drug Safety “Super-Office”; Management Support Is Goal

Apr 04 2011

House Approps Bill Would "Harden" Science Requirements For FDA Rules, Guidance

Jun 01 2011

Drug Shortage Legislation Gains Momentum With Bipartisan House Bill

Jun 27 2011

Accelerated Approval Program’s Future Is On The Line At <i>Avastin</i> Hearing

May 23 2011

"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected

Feb 14 2011

Antibiotics Could Get Double Exclusivity Under House Bill; FDA Makes Its Own Moves

Jun 20 2011

FDA Looks To Capitol Hill For New Authority For Globalization Plan

Jun 20 2011

CMS 2012 Budget Looks To Biosimilars, Brand/Generic Deals To Offset Costs

Feb 21 2011

Not Another FDAAA – Observers Expect Fewer FDA Reforms In PDUFA V

Jul 11 2011

Woodcock Defends Speed Of FDA Reviews, Cites 20 Approvals In First Half Of 2011

Jul 07 2011

Calls For Rx Imports Stay Alive: Montana, North Dakota Seek To Allow Residents To Buy From Canada

Apr 21 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window